Together with TrilliumBiO, we are excited to announce the US launch of Oncular™, bringing Oncobit’s uveal melanoma monitoring solution to the US through TrilliumBiO’s multi-accredited laboratory. Oncular™ enables real-time quantitative assessment of circulating tumor DNA (ctDNA) from a simple blood draw, bringing advanced personalized cancer monitoring to physicians across the United States. This launch marks an important step toward improving access to innovative molecular monitoring solutions for patients with uveal melanoma, a rare and historically underserved cancer. We are proud to support clinicians with actionable insights that enable more precise disease monitoring and patient management. To learn more: https://lnkd.in/e_GTUz2F #PrecisionOncology #LiquidBiopsy #ctDNA #UvealMelanoma #CancerDiagnostics #Oncology #PersonalizedMedicine Oncobit AG
Oncobit AG
Herstellung medizinischer Geräte
Schlieren, Zurich 1.611 Follower:innen
Enabling personalized cancer care
Info
Oncobit is a medtech UZH Spin-off, enabling personalized cancer care by matching patients to the best cancer treatment available. We are developing cancer-specific genomic fingerprinting and personalized monitoring tests and provide therapy decision support.
- Website
-
https://oncobit.com
Externer Link zu Oncobit AG
- Branche
- Herstellung medizinischer Geräte
- Größe
- 2–10 Beschäftigte
- Hauptsitz
- Schlieren, Zurich
- Art
- Privatunternehmen
- Gegründet
- 2018
Orte
-
Primär
Wegbeschreibung
Rütistrasse 16
Schlieren, Zurich 8952, CH
Beschäftigte von Oncobit AG
Updates
-
Oncobit AG hat dies direkt geteilt
Congratulations to all authors 👏🏻! What an important milestone in advancing #melanoma #monitoring with #ctDNA. We are proud that Oncobit AG’s solution could contribute to this work and look forward to what comes next!
Circulating tumor DNA (ctDNA) is moving from a translational biomarker toward clinical decision-making in melanoma. This international expert survey from the Melanoma World Society Study Group — based on real-world clinical vignettes — highlights ctDNA’s strongest value in MRD detection, relapse surveillance, and advanced-stage disease with clear momentum toward routine integration despite current barriers. Kudos to first authors Glenn Geidel & Nathan Fekade and the entire global consortium for this outstanding collaborative work. Proud to lead this effort together with Axel Hauschild. https://lnkd.in/dJPrGApj #Melanoma #ctDNA #LiquidBiopsy #MRD #PrecisionOncology #Immunotherapy #EADO #MWS #ELBS #UKEHamburg #HauttumorzentrumHamburg #UCCHamburg #FleurHiegeCentrum #HiegeStiftung #ADO #NVKH #MelanomInfoDeutschland #HKND #infoportalHautkrebs #ADF #OncoPulse #Oncobit
-
Oncobit AG hat dies direkt geteilt
We are pleased to announce the launch of a new joint EADO-EUMelaReg project focused on advancing cutaneous melanoma follow-up through the integration of circulating tumor DNA (ctDNA) into routine clinical practice. By closely reflecting real-world clinical practice and leveraging the strengths of the EUMelaReg registry the project aims to generate robust evidence for precision monitoring and help shape the future of melanoma care. Cancer centers interested in joining the project or learning more are warmly invited to reach out. To find out more: https://lnkd.in/eHJNvxad https://lnkd.in/ej7TbvCA #Melanoma #ctDNA #PrecisionMedicine #DigitalPCR #Oncology #RealWorldEvidence #EADO #EUMelaReg #Oncobit
-
-
Oncobit AG hat dies direkt geteilt
[PARTNERSHIP] 𝗪𝗲’𝗿𝗲 𝗽𝗿𝗼𝘂𝗱 𝘁𝗼 𝗮𝗻𝗻𝗼𝘂𝗻𝗰𝗲 𝗮 𝗻𝗲𝘄 𝘀𝘁𝗿𝗮𝘁𝗲𝗴𝗶𝗰 𝗽𝗮𝗿𝘁𝗻𝗲𝗿𝘀𝗵𝗶𝗽 𝗯𝗲𝘁𝘄𝗲𝗲𝗻 𝗜𝗗 𝗦𝗢𝗟𝗨𝗧𝗜𝗢𝗡𝗦 𝗮𝗻𝗱 𝗢𝗻𝗰𝗼𝗯𝗶𝘁 𝗔𝗚. Together, we are joining forces to accelerate and personalize cancer diagnosis and monitoring through the power of digital PCR. This collaboration brings together: 🔬 ID SOLUTIONS’ expertise in molecular oncology 💡 ONCOBIT’s innovative software and precision medicine solutions Together, we will develop a new generation of sensitive tests capable of: • Detecting actionable cancer markers from a simple blood sample 𝗶𝗻 𝘂𝗻𝗱𝗲𝗿 𝟮𝟰 𝗵𝗼𝘂𝗿𝘀 • Monitoring treatment effectiveness over time to support more precise and reactive clinical decisions Our common ambition is clear: 𝗺𝗮𝗸𝗲 𝗽𝗲𝗿𝘀𝗼𝗻𝗮𝗹𝗶𝘇𝗲𝗱 𝗰𝗮𝗻𝗰𝗲𝗿 𝗺𝗼𝗻𝗶𝘁𝗼𝗿𝗶𝗻𝗴 𝗮𝗰𝗰𝗲𝘀𝘀𝗶𝗯𝗹𝗲 𝘁𝗼 𝗲𝘃𝗲𝗿𝘆𝗼𝗻𝗲, 𝗲𝘃𝗲𝗿𝘆𝘄𝗵𝗲𝗿𝗲. A major step forward in providing patients with faster, more accurate and truly personalized care. To find out more : https://lnkd.in/eRWj52Xf
-
-
Oncobit is proud to partner with TrilliumBiO to bring our novel uveal melanoma monitoring solution to the U.S. This partnership will not only broaden access for U.S patients but also improve patient management by integrating diagnostic insights with emerging therapies. Together, we’re enabling personalized care for families and patients navigating this rare disease. Read more in our press release: https://lnkd.in/eU7shV9Y #Diagnostics #TrilliumBiO #Oncobit #CancerMonitoring #Oncology
-
🎉 We are excited to announce that Oncobit has successfully completed a capital increase of more than CHF 1.9 million This round was supported by both existing and new investors, including private business angels and the strategic investor ID Solutions (IDS). We are grateful for the continued trust and commitment of our shareholders and partners who share our mission to make precision cancer monitoring broadly accessible. The funding further strengthens our financial position and enables us to advance our clinical validation, regulatory, and commercialization efforts, as well as expand into additional cancer indications and new markets. A heartfelt thank you to everyone who continues to support our journey — together, we are helping shape the future of personalized cancer care. https://lnkd.in/exmbZ2cS #Oncobit #PrecisionOncology #Cancer #Monitoring #Innovation #HealthTech #SwissStartups
-
Oncobit will be attending both ESMO and SMR this year 😁! We are looking forward to connecting with current collaborators and meeting new partners who share our mission to enable personalized cancer care through precise and accessible ctDNA monitoring. Please reach out if you want to learn more about Oncobit™ PM, our IVDR-certified digital PCR solution for real-time, decentralized monitoring of melanoma patients - helping clinicians and researchers better understand tumor dynamics and improve treatment decisions. We’d love to connect! #ESMO2025 #SMR2025 #Oncobit #PersonalizedMedicine #ctDNA #Melanoma #DigitalPCR #CancerMonitoring
-
-
We are proud to announce that Oncobit AG has joined NAIPO, the National AI Initiative for Precision Oncology, selected as an Innosuisse Flagship Initiative. With our #cancer #monitoring solution, we look forward to contributing to this pioneering AI-powered precision oncology platform and working alongside leading partners to shape the future of #personalized #cancer #care.
Introducing… NAIPO — the National AI Initiative for Precision Oncology — selected as a Flagship Initiative by Innosuisse. 🔬 🤖 Rolling out over the next four years, the initiative aims to transform cancer care in Switzerland with artificial intelligence. NAIPO will develop a secure infrastructure to enable AI-powered precision oncology nationwide — ensuring that sensitive and personal health data remains protected while unlocking new possibilities for personalized, equitable, and effective treatments. With 21 partners across academia, healthcare, and industry, the initiative will: 🔬 Deploy advanced AI models across the patient journey 🧬 Accelerate biomarker and therapy discovery 📱 Create patient-facing tools and clinical decision platforms 🔐 Enable privacy-conscious, Swiss-hosted data collaboration Co-led by the EPFL AI Center and the ETH AI Center, NAIPO brings together a national effort to drive lasting impact in cancer research, care, and innovation. We look forward to sharing milestones and results as the project progresses. 👉 Read more: https://lnkd.in/gFhnaj93 #AIforHealth EPFL ETH Zürich University of Basel University of Bern University of Geneva University of Zurich University of Applied Sciences and Arts Northwestern Switzerland FHNW Berner Fachhochschule BFH University Hospital Basel HUG - Hopitaux Universitaires de Genève Insel Gruppe Universitätsspital Zürich Kantonsspital Aarau AG Luzerner Kantonsspital Kantonsspital Baden AG Ente Ospedaliero Cantonale (EOC) Kantonsspital Winterthur Roche SOPHiA GENETICS Debiopharm Switch Tune Insight Hedera Dx Oncobit AG Navignostics AG Sawera Health Foundation Swiss Data Science Center CSCS Health 2030 Genome Center Swiss Digital Pathology Initiative Hirslanden Swiss Medical Network EPFL School of Life Sciences EPFL School of Computer and Communication Sciences EPFL School of Engineering
-
-
Oncobit AG hat dies direkt geteilt
🏆 Herzliche Gratulation, Oncobit AG! Beim 7. Digital Health Lab Day der ZHAW überzeugte das Startup Oncobit gleich doppelt – sowohl das Publikum als auch die Jury wählte das vielversprechende Jungunternehmen in der Kategorie "Best Pitching Startup" zur Siegerin👏 𝗗𝗼𝗰𝗵, 𝘄𝗮𝘀 𝗯𝗶𝗲𝘁𝗲𝘁 𝗢𝗻𝗰𝗼𝗯𝗶𝘁? Das Team rund um die (Co-)Founderin Claudia verfolgt das Ziel, die Behandlung von Patient:innen durch hochpräzise und innovative Lösungen zur Krebsüberwachung zu verbessern. Mit modernsten Technologien entwickelt Oncobit krebsspezifische Überwachungstests, die auf einer einfachen Blutprobe basieren. Damit erhalten Ärzt:innen präzise, zuverlässige Informationen für Therapieentscheidungen – für die bestmögliche Behandlung bei optimaler Kosteneffizienz. Wir sind gespannt, wie das Startup die Zukunft der Krebsbehandlung weiter mitgestaltet! #onkologie #krebstherapie #personalisiertemedizin #startup #digitalhealth
-
-
Oncobit AG hat dies direkt geteilt
🏆 Congratulations, you did it! Oncobit AG won the Startup Award twice at Digital Health Lab Day 2025. After a very professional and inspiring pitching session with eight finalists, Oncobit clearly won the audience and jury awards. Applause also goes to the second and third place winners, Heureka Health, BIOS Medical and Collabree Ltd, as well as all the finalists, who took the challenge! 🚀 🙌 The startup finalists are (in alphabetical order): ➡️ BIOS Medical ➡️ Collabree Ltd ➡️ DeepPsy AG ➡️ DRYLABZ ➡️ Go Healthy & Co ➡️ Healactively ➡️ Heureka Health ➡️ Oncobit AG 👏 Big thanks to the Jury Members: Beata Dinger, Diana Hardie, Dario Stähelin, Matthias Mettler, Simon Nebel, Stefan Lienhard, Yana Yoncheva 👏 And the Startup-Track Sponsor: Scope Law Main Partners: Innovation Zurich, Institut für Wirtschaftsinformatik ZHAW, Kanton Zürich, Roche Other Sponsors: , Heureka Health, DayOne - Healthtech Innovation, VAMED Schweiz, Innovation Booster Artificial Intelligence powered by Innosuisse, ZHAW School of Management and Law, ZHAW-WIG Winterthurer Institut für Gesundheitsökonomie - ZHAW Digital Health Lab Michael Eitle - Michael Kuhn #digitalhealth #startups #pitching #winner #award #winterthur #dhld
-